Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Ph.D. Tom Wickham
Vice President Research and Development at Rubius Therapeutics
About the author:
Tom Wickham, Ph.D., VP of Research & Development at Rubius Therapeutics, is responsible for the discovery and development of novel therapeutic agents in different therapeutic areas, based on his over twenty years in drug development in immuno-oncology, oncology, and gene therapy that spans preclinical through later stage clinical development.
Dr. Wickham most recently comes from Merrimack Pharmaceuticals where he served as Vice President, R & D and led preclinical through Phase 2 development of a targeted chemotherapy in breast cancer. Prior to Merrimack Dr. Wickham was Senior Director of Preclinical Pharmacology and led efforts at EMD Lexigen (now Merck-Serono) to advance immuno-oncology drugs through preclinical development and into Phase I trials. As Senior Director of Preclinical Sciences at GenVec, Inc. he led the advancement of a targeted gene delivery platform for oncology, cardiovascular, infectious disease, and genetic disease applications.
Dr. Wickham holds a B.S. in chemical/biomedical engineering from Carnegie Mellon University and a Ph.D. in biochemical engineering from Cornell University, and pursued his postdoctoral training at the Scripps Research Institute in the department of immunology.
Posts by Ph.D. Tom Wickham
Posted on January 17th, 2017 in Pharma R&D
In pursuit of our research efforts at Rubius Therapuetics, our key priorities are to develop our technology platform capability, generate data that broadly supports its application in key therapeutic areas, Continue reading “Our R&D Priorities, Our Challenges, and How The Hive Helps Us Overcome Them” »